

Human Mucormycosis

Parisa Badiee*

Alborzi Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding author: Parisa Badiee, Alborzi Clinical Microbiology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran, Tel: 98-71-3647-4292; Fax: 98 71-3647-4303; E-mail: badieep@yahoo.com

Received date: December 09, 2015; Accepted date: December 12, 2015; Published date: December 18, 2015

Copyright: © 2015 Badiee P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Incidence of mucormycosis, the severe infection in immunocompromised and immunocompetent patients [1,2], is increased in recent years. In the United States, 63% of non *Aspergillus* mold infections in transplant recipients were caused by Mucoral family [3] with mortality rate of 22%, 25%, 48% and 79% for cutaneous, rhino-cerebral, pulmonary and disseminated infections, respectively [3]. In US and France, *Rhizopus* species are the most common genera [1,3].

The presentation type of this infection usually depends on the underlying host conditions [4]. Hyperglycemia and low pH in diabetic patients are the most important risk factors. The common risk groups include those on therapeutic interventions corticosteroid therapy, solid tumors and solid organ transplant recipients, acquired or congenital neutropenic patients, those with hematologic disorders and hematopoietic stem cell transplant recipients. In last decades, a link has been reported between infection with the *Rhizopus* species and resistant gram-negative bacteria which can produce endosymbiotic toxin [4,5]. Hemodialysis patients under treatment with deferoxamine, due to high concentration of free iron in plasma and tissues are at risk for mucormycosis [6]. The common presentations are rhino-orbital-cerebral involvement, pulmonary and gastrointestinal infection, and invasive mucormycosis (central nervous system infection).

Mucoral spores with 3-11µm diameters can be easily aerosolized and dispersed throughout the environment and inhaled by human. Human may also be infected by taking infected food through the gastrointestinal tract, and also by direct inoculation through skin (trauma, burn) or central venous catheters [7]. Invasion to human endothelial cells is related to host receptor (the glucose-regulated protein 78) and iron (expression of the high affinity iron permease gene and its product). Therefore, diabetic patients with high serum iron level and glucose concentrations are more susceptible to mucormycosis than other high risk patients. Mucorales could invade the tissues by proteolytic, lipolytic, and glycosidic enzymes and also with metabolite products like mycotoxins such as agroclavine [6,8].

The first barriers to immune defense in human are ciliated bronchial cells and their mucus that lead sporangiospores away from alveoli by coughing. Macrophages and neutrophils play the major role in immunedefense. Spores are phagocytosed by macrophages oxidative killing and hyphae are damaged by neutrophil oxidative cytotoxic system and chemotactically attracted. Pulmonary alveolar macrophages damage the invading organisms and to regulate innate immune response secrete cytokines and chemokines to destroy sporangiospores before they terminate to become hyphae. In hosts with diabetes, the monocytes/macrophages are dysfunctional and fail [5,9,10].

The gold standard test for diagnosis is the isolation of organism from clinical samples. The hyphae of this family are delicate and frequently destroyed in the process of sample preparation, therefore, isolation of organisms from clinical samples remains difficult. Serological diagnostic method for these infections is not available but use of molecular methods like a polymerase chain reaction technique is recommended in the literature [11].

Conclusion

Mucormycosis has emerged as severe infection in immunocompromised and immunocompetent patients in many health centers worldwide. Epidemiology, diagnosis and treatment are with many unresolved issues and to guide the best management newer diagnostic tests to initiate appropriate treatment are suggested.

Acknowledgment

Our thanks are due to Hassan Khajehei for his help with language copy editing.

References

1. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, et al. (2012) A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). *Clin Infect Dis* 54: S35-S43.
2. Badiee P, Jafarpour Z, Alborzi A, Haddadi P, Rasuli M, et al. (2012) Orbital mucormycosis in an immunocompetent individual. *Iran J Microbiol* 4: 210-214.
3. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, et al. (2011) Invasive non-*Aspergillus* mold infections in transplant recipients, United States, 2001-2006. *Emerg Infect Dis* 17: 1855-1864.
4. Mantadakis E, Samonis G (2009) Clinical presentation of zygomycosis. *Clin Microbiol Infect* 15: 15-20.
5. Chayakulkeeree M, Ghannoum MA, Perfect JR (2006) Zygomycosis: the re-emerging fungal infection. *Eur J Clin Microb and Infec Dis* 25: 215-229.
6. Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, et al. (2010) The high affinity iron permease is a key virulence factor required for *Rhizopus oryzae* pathogenesis. *Mol Microbiol* 77: 587-604.
7. Ribes JA, Vanover-Sams CL, Baker DL (2000) Zygomycetes in human disease. *Clin Microb Rev* 13: 236-301.
8. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, et al. (2010) The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice (2010). *J Clin Invest* 120: 1914-1924.
9. Ibrahim AS, Spellberg B, Avanesian V, Fu Y, Edwards JE Jr (2005). *Rhizopus oryzae* adheres to, is phagocytosed by, and damages endothelial cells in vitro. *Infect Immun* 73: 778-783.
10. Morace G, Borghi E (2012) Invasive mold infections: virulence and pathogenesis of mucorales. *Int J Microbiol* 2012: 349278.
11. Badiee P, Arastefar A, Jafarian H (2013) Comparison of histopathological analysis, culture and polymerase chain reaction assays to detect mucormycosis in biopsy and blood specimens. *Iran J Microbiol* 5: 406-410.

